相关临床试验
36
2 进行中
药物批准
5
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
2
5.6%
已完成
12
33.3%
招募中
1
2.8%
终止
1
2.8%
- AGC Biologics has been selected by Teikoku Seiyaku to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteinase-7 therapy targeting lumbar disc herniation. - The partnership leverages AGC Biologics' global network with initial cell bank creation in Heidelberg, Germany, followed by process development and GMP manufacturing in Chiba, Japan for clinical trials. - This collaboration highlights AGC Biologics' unique position as the only CDMO offering microbial manufacturing across three continents, providing supply chain security and flexibility for drug developers. - The therapy represents a potentially less invasive treatment option for patients suffering from lumbar disc herniation, addressing an important unmet medical need.
- MEDIPOST has secured $140 million in funding led by Skylake Equity Partners and Crescendo Equity Partners to accelerate Phase III clinical trials of its stem cell therapy for knee osteoarthritis in the U.S., with trial initiation anticipated in early 2026. - The company has formed an exclusive partnership with Teikoku Seiyaku for commercialization of CARTISTEM in Japan, including $18 million in upfront and milestone payments plus additional sales-based milestones. - CARTISTEM, an allogeneic umbilical cord blood-derived mesenchymal stem cell therapy, has been approved in South Korea since 2012 and used in over 35,000 patients for treating moderate to severe knee osteoarthritis. - The therapy represents a potential disease-modifying osteoarthritis drug (DMOAD) designed to regenerate cartilage, addressing significant unmet medical needs in osteoarthritis treatment.
